At a glance
| Reference names | Bremelanotide; PT-141 |
|---|---|
| Approved context | Acquired, generalized HSDD in premenopausal women |
| Target family | Melanocortin receptors |
| Evidence | Two phase 3 placebo-controlled trials |
| Key boundary | Prescription indication does not extend to general enhancement |
Overview
Bremelanotide and PT-141 are two names for the same active molecule, rather than two different treatments. The approved product, Vyleesi, addresses acquired, generalized hypoactive sexual desire disorder when symptoms cause distress and are not explained by another medical condition, a relationship problem, or a medicine. This is a carefully defined clinical population. The relevant research measured changes in desire and associated distress; it did not establish a general sexual-performance enhancer. A research vial carrying the PT-141 name cannot be assumed equivalent to an approved, quality-controlled prescription product.
How it works
Bremelanotide activates melanocortin receptors. Its clinical effect on desire is thought to involve central pathways, although the exact pathway responsible for benefit is not fully established. This differs from simply increasing genital blood flow. Receptor activity also helps explain why pigment changes and cardiovascular effects deserve attention: a peptide can influence several tissues even when the intended treatment target is specific.
What the trials established
The RECONNECT program randomized 1,267 women across two trials lasting 24 weeks. Desire scores and distress related to low desire improved more with bremelanotide than placebo. These were questionnaire outcomes in selected participants; statistical improvement does not mean every participant experienced a clinically useful change. Most participants were White and recruited in the United States, which limits certainty about generalizability.
Supporting sources [2]
Safety and suitability
The label contraindicates use in uncontrolled hypertension or known cardiovascular disease. Transient blood-pressure increases, nausea, headache, flushing, vomiting, and sometimes persistent focal hyperpigmentation are important considerations. Slower gastric emptying can alter absorption of oral medicines. These issues make medication and cardiovascular review part of assessing suitability, rather than an optional detail.
Supporting sources [1]
Approval and identity
FDA approval attaches to the prescription product and labeled population. It does not validate every product sold as PT-141, and it does not establish efficacy in men, postmenopausal women, or people seeking enhancement without HSDD. The PT-141 name therefore does not describe an additional medicine with broader approved uses or a separate safety profile.
Supporting sources [1]
Frequently asked questions
Is PT-141 a different peptide from bremelanotide?
No. PT-141 is a development name for the same molecule. A product sold under that name is not necessarily the approved Vyleesi formulation.
Is it approved for men or general performance enhancement?
The U.S. indication cited here is acquired, generalized HSDD in premenopausal women. Results in that population cannot establish broader enhancement claims.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Synthetic cyclic melanocortin peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- FDA prescribing information: Vyleesi (bremelanotide) ↗Regulatory source · Checked 2026-10-27
- Bremelanotide for HSDD: two randomized phase 3 trials ↗Clinical trial source · Checked 2026-10-27